Bookbuilding IPO | ₹402 Cr | Listed at BSE, NSE | Wed, Aug 4, 2021 - Fri, Aug 6, 2021
Windlas Biotech IPO is a book build issue of ₹401.54 crores. The issue is a combination of fresh issue of 0.36 crore shares aggregating to ₹165.00 crores and offer for sale of 0.51 crore shares aggregating to ₹236.54 crores.
Windlas Biotech IPO bidding started from Aug 4, 2021 and ended on Aug 6, 2021. The allotment for Windlas Biotech IPO was finalized on Aug 11, 2021. The shares got listed on BSE, NSE on Aug 16, 2021.
Windlas Biotech IPO price band is set at ₹460 per share. The lot size for an application is 30. The minimum amount of investment required by an retail is ₹13,800 (30 shares) (based on upper price). The lot size investment for sNII is 15 lots (450 shares), amounting to ₹2,07,000, and for bNII, it is 73 lots (2,190 shares), amounting to ₹10,07,400.
Dam Capital Advisors Ltd. is the book running lead manager and MUFG Intime India Pvt.Ltd. is the registrar of the issue.
Refer to Windlas Biotech IPO RHP for detailed Information.
IPO Open
Wed, Aug 4, 2021
IPO Close
Fri, Aug 6, 2021
Issue Price
₹460 per share
Market Cap (Pre-IPO)
₹1,002.54 Cr
| IPO Date | 4 to 6 Aug, 2021 |
| Listed on | Mon, Aug 16, 2021 |
| Face Value | ₹5 per share |
| Price Band | ₹448 to ₹460 |
| Issue Price | ₹460 per share |
| Lot Size | 30 Shares |
| Sale Type | Fresh capital cum OFS |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Total Issue Size | 87,29,023 shares (agg. up to ₹402 Cr) |
| Fresh Issue | 35,86,956 shares (agg. up to ₹165 Cr) |
| Offer for Sale | 51,42,067 shares of ₹5 (agg. up to ₹237 Cr) |
| Share Holding Pre Issue | 1,82,07,419 shares |
| Share Holding Post Issue | 2,17,94,375 shares |
| BSE Script Code / NSE Symbol | 543329 / WINDLAS |
| ISIN | INE0H5O01029 |
Windlas Biotech IPO comprises a total issue size of 87,29,023 shares. Out of which, 43,64,510 (50.00%) are allocated to QIB, 13,09,354 (15.00%) allocated to NII 30,55,159 (35.00%) allocated to RII.
| Investor Category | Shares Offered | % of Total Issue | Max Allottees |
|---|---|---|---|
| QIB Shares Offered | 43,64,510 | 50.00% | NA |
| − Anchor Investor Shares Offered | 26,18,706 | 30.00% | NA |
| − QIB (Ex. Anchor) Shares Offered | 17,45,804 | 20.00% | NA |
| NII (HNI) Shares Offered | 13,09,354 | 15.00% | NA |
| Retail Shares Offered | 30,55,159 | 35.00% | 1,01,838 |
| Total Shares Offered | 87,29,023 | 100.00% |
Investors can bid for a minimum of 30 shares and in multiples thereof.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 30 | ₹13,800 |
| Retail (Max) | 14 | 420 | ₹1,93,200 |
| S-HNI (Min) | 15 | 450 | ₹2,07,000 |
| S-HNI (Max) | 72 | 2,160 | ₹9,93,600 |
| B-HNI (Min) | 73 | 2,190 | ₹10,07,400 |
Windlas Biotech IPO raises ₹120.46 crore from anchor investors. Windlas Biotech IPO Anchor bid date is August 3, 2021.
📝 Anchor Investors Letter (PDF)
| Bid Date | Tue, Aug 3, 2021 |
| Shares Offered | 26,18,706 |
| Anchor Portion (₹ Cr.) | 120.46 |
| Anchor lock-in period end date for 50% shares (30 Days) | Fri, Sep 10, 2021 |
| Anchor lock-in period end date for remaining shares (90 Days) | Tue, Nov 9, 2021 |
Incorporated in 2001, Windlas Biotech Ltd is one of the leading companies in the pharmaceutical formulations contract development and manufacturing organizations (CDMO) segment in India. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
It further sells its own branded products in the trade generics and OTC markets. Currently, the focus of the company is to launch complex generic products in the chronic therapeutic category related to lifestyle-related disorders. The business operates in 3 verticals; 1. CDMO Products and services, 2. Domestic trade generics and Over-the-counter (OTC) market (nutraceutical and health supplement products), and 3. Export.
Leading pharma companies i.e. Pfizer Ltd, Sanofi India Ltd, Cadila Healthcare Ltd, Emcure Pharmaceuticals Ltd, Eris Lifesciences Ltd, Intas Pharmaceuticals Ltd, and Systopic Laboratories Private Limited are some of the marquee customers of Windlas Biotech. Its manufacturing facilities are located at Dehradun with an installed operating capacity of 7,063.83 million tablets/ capsules, 54.46 million pouch/ sachet, and 61.08 million liquid bottles.
Competitive strengths
| Period Ended |
|---|
| Amount in ₹ Crore |
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Purchase of equipment required for (i) capacity expansion of the existing facility at the Dehradun Plant – IV; and (ii) addition of injectables dosage capability at our existing facility at Dehradun Plant – II | 50.00 |
| 2 | Funding incremental working capital requirements of the Company | 47.56 |
| 3 | Repayment/prepayment of certain of the borrowings | 20.00 |
| 4 | General corporate purposes( | 34.60 |
The Windlas Biotech IPO is subscribed 22.44 times on August 6, 2021 6:50:00 PM (Day 3). The public issue subscribed 24.22 times in the retail category, 24.4 times in the QIB category, and 15.73 times in the NII category. Check Day by Day Subscription Details (Live Status)
| Category | Subscription (times) | Shares Offered | Shares bid for |
|---|---|---|---|
| QIB | 24.4 | 17,23,700 | 4,20,65,880 |
| NII | 15.73 | 13,23,766 | 2,08,26,420 |
| Retail | 24.22 | 30,88,786 | 7,47,96,420 |
| Total | 22.44 | 61,36,252 | 13,76,88,720 |
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Book Running Lead Managers’ fees | 12.12 |
| 2 | Commission/processing fee for SCSBs and the Banker to the Offer. Brokerage, underwriting commission and selling commission and bidding charges for Members of the Syndicate, Registered Brokers, RTAs and CDPs | 5.55 |
| 3 | Fees payable to the Registrar to the Offer | 0.28 |
| 4 | Fees payable to the other advisors to the Offer | 1.16 |
| 5 | Listing fees, SEBI filing fees, upload fees, BSE & NSE processing fees, book building software fees and other regulatory expenses | 3.07 |
| 6 | Printing and stationery | 1.29 |
| 7 | Advertising and marketing expenses | 1.99 |
| 8 | Fee payable to legal counsels | 3.98 |
| 9 | Miscellaneous | 0.74 |
| Price Details | BSE | NSE |
|---|---|---|
| Final Issue Price | ₹460.00 | ₹460.00 |
| Open | ₹439.00 | ₹437.00 |
| Low | ₹405.00 | ₹405.00 |
| High | ₹452.10 | ₹452.00 |
| Last Trade | ₹406.70 | ₹407.15 |
Windlas Biotech IPO is a main-board IPO of 87,29,023 equity shares of the face value of ₹5 aggregating up to ₹402 Crores. The issue is priced at ₹460 per share. The minimum order quantity is 30.
The IPO opens on Wed, Aug 4, 2021, and closes on Fri, Aug 6, 2021.
MUFG Intime India Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Zerodha customers can apply online in Windlas Biotech IPO using UPI as a payment gateway. Zerodha customers can apply in Windlas Biotech IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Windlas Biotech IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Windlas Biotech IPO opens on Wed, Aug 4, 2021 and closes on Fri, Aug 6, 2021.
Windlas Biotech IPO lot size is 30, and the minimum amount required for application is ₹13,800.
You can apply in Windlas Biotech IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Windlas Biotech IPO will be done on Wednesday, August 11, 2021, and the allotted shares will be credited to your demat account by Fri, Aug 13, 2021. Check the Windlas Biotech IPO allotment status.
The Windlas Biotech IPO listing date is on Mon, Aug 16, 2021.
